Johnson & Johnson Ordered to Pay $8 Billion in Risperdal Case Involving Male Breast Growth
Johnson & Johnson has been ordered to pay $8 billion in punitive damages in a case involving the way that the anti-psychotic drug Risperdal was marketed. Some male patients have argued that the drug caused them to grow large breasts and that the company downplayed this side effect when marketing the drug to doctors.